中国医师杂志
中國醫師雜誌
중국의사잡지
JOURNAL OF CHINESE PHYSICIAN
2013年
11期
1519-1521
,共3页
肝炎,乙型,慢性/药物疗法%拉米夫定/治疗应用%腺嘌呤/类似物和衍生物%腺嘌呤/治疗应用%药物疗法,联合%膦酸类/治疗应用
肝炎,乙型,慢性/藥物療法%拉米伕定/治療應用%腺嘌呤/類似物和衍生物%腺嘌呤/治療應用%藥物療法,聯閤%膦痠類/治療應用
간염,을형,만성/약물요법%랍미부정/치료응용%선표령/유사물화연생물%선표령/치료응용%약물요법,연합%련산류/치료응용
Hepatitis B,chronic/drug therapy%Lamivudine/therapeutic use%Adenine/analogs & derivatives%Adenine/therapeutic use%Drug therapy,combination%Phosphonic acids/therapeutic use
目的 研究拉米夫定优化治疗与拉米夫定初始联合阿德福韦酯治疗慢性乙型肝炎的临床疗效.方法 将98例慢性乙肝患者按随机数字表法分为优化治疗组与初始联合组,优化治疗组用拉米夫定优化疗法,初始联合组用拉米夫定初始联合阿德福韦酯进行治疗,每12周对病毒学、血清学、生物化学等指标进行检测,分析48周的疗效.结果 两组患者治疗前基线情况有可比性(P＞0.05).治疗48周初始联合组HBV DNA阴转率、e抗原阴转率、耐药率分别为86％、37％、0,优化治疗组为59％、12％、18％,差异有统计学意义(P＜0.05).初始联合组e抗原血清转换率、ALT复常率分别为23％、91％,优化治疗组分别为6％、86％,两组差异无统计学意义(P＞0.05),两组不良反应发生率差异无统计学意义(P＞0.05).结论 初始联合组相比拉米夫定优化治疗组可取得更高的HBV-DNA阴转率、e抗原阴转率,更低耐药率,安全性较好.
目的 研究拉米伕定優化治療與拉米伕定初始聯閤阿德福韋酯治療慢性乙型肝炎的臨床療效.方法 將98例慢性乙肝患者按隨機數字錶法分為優化治療組與初始聯閤組,優化治療組用拉米伕定優化療法,初始聯閤組用拉米伕定初始聯閤阿德福韋酯進行治療,每12週對病毒學、血清學、生物化學等指標進行檢測,分析48週的療效.結果 兩組患者治療前基線情況有可比性(P＞0.05).治療48週初始聯閤組HBV DNA陰轉率、e抗原陰轉率、耐藥率分彆為86％、37％、0,優化治療組為59％、12％、18％,差異有統計學意義(P＜0.05).初始聯閤組e抗原血清轉換率、ALT複常率分彆為23％、91％,優化治療組分彆為6％、86％,兩組差異無統計學意義(P＞0.05),兩組不良反應髮生率差異無統計學意義(P＞0.05).結論 初始聯閤組相比拉米伕定優化治療組可取得更高的HBV-DNA陰轉率、e抗原陰轉率,更低耐藥率,安全性較好.
목적 연구랍미부정우화치료여랍미부정초시연합아덕복위지치료만성을형간염적림상료효.방법 장98례만성을간환자안수궤수자표법분위우화치료조여초시연합조,우화치료조용랍미부정우화요법,초시연합조용랍미부정초시연합아덕복위지진행치료,매12주대병독학、혈청학、생물화학등지표진행검측,분석48주적료효.결과 량조환자치료전기선정황유가비성(P＞0.05).치료48주초시연합조HBV DNA음전솔、e항원음전솔、내약솔분별위86％、37％、0,우화치료조위59％、12％、18％,차이유통계학의의(P＜0.05).초시연합조e항원혈청전환솔、ALT복상솔분별위23％、91％,우화치료조분별위6％、86％,량조차이무통계학의의(P＞0.05),량조불량반응발생솔차이무통계학의의(P＞0.05).결론 초시연합조상비랍미부정우화치료조가취득경고적HBV-DNA음전솔、e항원음전솔,경저내약솔,안전성교호.
Objective To investigate the clinical efficacy of the optimization of treatment with lamivudine or de novo combination therapy with lamivudine and adefovir dipivoxil.Methods A total of 98 cases of chronic hepatitis B patients were randomly divided into optimization of treatment group and de novo combination therapy group,optimization of treatment group treated with lamivudine optimization therapy,de novo combination therapy group treated with lamivudine and adefovir dipivoxil,virological,serological,biochemical and other indices were detected every 12 weeks,analyzed treatment effect after 48 weeks.Results Two groups were comparable baseline before treatment(P ＞0.05).HBV DNA negative rate,e antigen-negative rate,and resistance rates at week 48 were 86％,37％,and 0 in the de novo combination therapy group,and 59％,12％ and 18％ in the optimized treatment group (P ＜0.05).The e antigen seroconversion and ALT normalization rates were 23％ and 91％ in the de novo combination group,and 6％ and 86％ in the optimized treatment group (P ＞0.05).There was similar incidence of adverse reactions.Conclusions Compared to the de novo combination therapy group,the lamivudine-optimized treatment group can achieve higher HBV-DNA negative rate,e antigen-negative rate,lower resistance rates,and good safety.
